MedTrace Logo

Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia

NCT04906083 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-06-07

No results posted yet for this study

Summary

End stage liver disease is prone to thrombocytopenia. This study is a multi-center, randomized, prospective, randomized controlled Phase IV Clinical trial to discuss the Efficacy and Safety of Avatrombopag in Patients with End-stage Liver Disease and Thrombocytopenia.

Conditions

Interventions

DRUG

Avatrombopag

Avatrombopag: PLT：30\~50×10\^9/L patients, 40 mg/d; PLT：\<30×10\^9/L patients, 60 mg/d.

DRUG

Standard medical treatment

Standard medical treatment included transmetil, compound glycyrrhizinate, reduced glutathione and hepatocyte growth factor, et. al.

Sponsors & Collaborators

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • The First Affiliated Hospital of Nanchang University

    collaborator OTHER

  • Taihe Hospital, Hubei University of Medicine

    collaborator UNKNOWN

  • The First Hospital of Jilin University

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Qin Ning, MD., PhD. · Department of Infectious Disease, Tongji Hospital, Tongji Medical College, HUST

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906083 on ClinicalTrials.gov